* indicates required field
Length: 1
Source of Standard: NAACCR
Section Name: Stage/Prognostic Factors
Year Implemented: 2018
Version Implemented: 18
Record Types: A, M, C, I
XML NAACCR ID: serumBeta2MicroglobulinPretxLvl
Parent XML Element: Tumor
Required Status:
NPCR Collect: . - No recommendations
CoC Collect: RS - Required, site specific
SEER Collect: RS - Required, site specific
CCCR Collect: RS* - Required, site specific; when available
Description:
Serum Beta-2 Microglobulin is a protein that is found on the surface of many cells and plentiful on the surface of white blood cells. Increased production or destruction of these cells causes Serum β2 (beta-2) Microglobulin level to increase. Elevated Serum β2 (beta-2) Microglobulin level is a prognostic factor for plasma cell myeloma.
Rationale:
Serum Beta-2 Microglobulin Pretreatment Level is a prognostic factor required in AJCC 8th edition, Chapter 82 Plasma Cell Myeloma and Plasma Cell Disorders, for staging of plasma cell myeloma.
Item Data Type:
digits
Allowable Values
0-2, 5, 7, 9
Codes:
0 |
β2-microglobulin \<3.5 mg/L |
|---|---|
1 |
β2-microglobulin =3.5 mg/L \<5.5 mg/L |
2 |
β2-microglobulin =5.5 mg/L |
5 |
Schema Discriminator 1: Plasma Cell Myeloma Terminology coded to 1 or 9 |
7 |
Test ordered, results not in chart |
9 |
Not documented in medical record Serum Beta-2 Microglobulin Pretreatment Level not assessed or unknown if assessed |
Code Notes:
Each Site-Specific Data Item (SSDI) applies only to selected primary sites, histologies, and years of diagnosis. Depending on applicability and standard-setter requirements, SSDIs may be left blank.